CognatiQ

FutureCeuticals, Aura Scientific Settle IP Dispute Over Cognitive Ingredient

Momence, Illinois – September 08, 2026 -- FutureCeuticals, Inc. and Aura Scientific have settled a patent and trademark lawsuit centered on Aura's NeuroRush® ingredient and FutureCeuticals' whole coffee fruit extract sold as CognatiQ® and NeuroFactor®.

Settlement terminates Aura's NeuroRush ingredient and validates FutureCeuticals' IP

The resolution ends production of NeuroRush® and confirms the enforceability of FutureCeuticals' intellectual property covering its whole coffee fruit extract. J. Randal Wexler, Vice President and Chief Legal Officer at FutureCeuticals, said Aura's acknowledgment of the IP's validity reinforces its market value and supports continued investment in clinical research.

FutureCeuticals, Aura Scientific Settle IP Suit Over Cognitive Ingredient

Momence, Ill. – September 08, 2026 -- FutureCeuticals, Inc. and Aura Scientific have resolved a patent and trademark lawsuit centered on Aura's NeuroRush ingredient, with Aura agreeing to discontinue NeuroRush and transition to FutureCeuticals' CognatiQ whole coffee fruit extract.

Legal dispute ends with Aura exiting NeuroRush ingredient line

The lawsuit involved FutureCeuticals' cognitive health intellectual property tied to its whole coffee fruit extract, sold under the tradenames CognatiQ and NeuroFactor. J. Randal Wexler, FutureCeuticals' Vice President & General Counsel, said Aura's acknowledgment of the IP's validity reinforces its market strength. Wexler noted the company's IP enforcement protects continued investment in clinical research while safeguarding customer and partner interests.

FutureCeuticals Settles IP Dispute, Aura to Sell CognatiQ

Momence, Illinois – September 08, 2026 -- FutureCeuticals, Inc. and Aura Scientific have settled a patent and trademark dispute over Aura's cognitive-health ingredient "NeuroRush," ending the product and replacing it with a new distribution partnership for FutureCeuticals' whole coffee cherry extract, sold as "CognatiQ" and "NeuroFactor."

Settlement terminates NeuroRush, validates FutureCeuticals' IP portfolio

The resolution confirms the validity of FutureCeuticals' intellectual property in the cognitive health ingredient category, according to J. Randal Wexler, the company's Vice President and General Counsel. Aura's NeuroRush ingredient will be discontinued as part of the agreement.